Medicaid; excluding prescription drug services from certain provisions; directing certain program delivery model. Effective date.
SB252 revises Oklahoma’s Medicaid managed care framework under the state’s “Ensuring Access to Medicaid Act.” The bill directs the Oklahoma Health Care Authority (OHCA) to continue using capitated contracts for most Medicaid services, but it carves prescription drug services out of the managed care model and requires those services to be delivered through a fee-for-service arrangement directly administered by OHCA, subject to federal approval. It also preserves separate contracting for dental services and a Children’s Specialty Plan, while requiring OHCA to seek federal approval before implementing the broader transformation.
The bill further tightens the structure of Medicaid contracting by requiring statewide capitated contracts to include medical, behavioral health, and pharmacy services in general contract design, but then specifically excluding prescription drug services from the managed-care delivery model and prohibiting contracts with pharmacy benefit managers. It requires contracted entities to have shared governance with Oklahoma providers, use a single OHCA-established drug formulary, maintain broad pharmacy access, and submit health information exchange data. The bill also extends and updates provider reimbursement rules, including minimum reimbursement floors, value-based payment options, special rules for rural health clinics, CCBHCs, ambulance services, anesthesia, and pharmacy payments.
In practical terms, SB252 would amend multiple sections of Oklahoma statutes governing Medicaid capitated contracts, contracted entity responsibilities, and reimbursement standards. It would change how prescription drugs are paid for in SoonerCare by shifting them from managed care to direct state administration, while leaving the rest of the managed-care structure in place for eligible populations. The bill also adds or reinforces statutory requirements for contract awards, provider-led and provider-owned entities, medical loss ratio compliance, primary care spending targets, and annual capitation rate updates.
The overall sentiment reflected by the bill text is pro-reform and pro-provider, with a clear emphasis on preserving state control, provider participation, and reimbursement protections within Medicaid managed care. Although no committee transcripts or recorded votes were provided, the bill’s structure suggests support for limiting pharmacy benefit manager involvement and for ensuring direct payment and access protections for providers and pharmacies. At the same time, the bill appears designed to avoid disruption by conditioning implementation on federal approval and allowing delays for financial or operational readiness.
The main points of contention are likely to be the carve-out of prescription drug services from capitated managed care, the prohibition on pharmacy benefit managers, and the administrative complexity of transitioning drug coverage back to OHCA. Another likely issue is the bill’s preference for provider-led and provider-owned entities, which may be viewed as beneficial by provider groups but potentially restrictive by other managed-care bidders. The requirement for federal approval and budget-neutral waiver treatment also indicates that implementation depends on CMS approval, which could be a practical and policy hurdle.
SB252 would amend Oklahoma Medicaid statutes to exclude prescription drug services from certain capitated managed-care provisions and require OHCA to administer those drugs through a fee-for-service model, with direct reimbursement to pharmacists and pharmacy providers. It would also revise contracting, governance, pharmacy access, reimbursement, and quality-payment rules for Medicaid managed care entities, affecting OHCA, contracted entities, providers, pharmacies, and Medicaid enrollees. The bill becomes effective November 1, 2025.
No committee discussion or vote history was provided, so there is no recorded legislative debate to summarize. Based on the bill text, the measure appears generally supportive of provider participation, direct state oversight of pharmacy benefits, and reimbursement protections, while also signaling caution by requiring federal approval before implementation. The absence of recorded opposition or support in the supplied materials means the overall sentiment can only be inferred from the bill’s policy choices rather than from legislative testimony or votes.
The most notable likely contention is the bill’s removal of prescription drug services from capitated managed care and its ban on pharmacy benefit managers, which would shift administrative and financial control away from managed-care contractors. Managed-care organizations and PBMs could oppose those changes, while pharmacies and some providers may support them. Another likely point of debate is the bill’s preferential treatment for provider-led and provider-owned entities in contract awards, which may be favored by local provider groups but challenged by other bidders or insurers. The requirement for CMS approval and the detailed transition rules may also raise concerns about feasibility, timing, and federal waiver compliance.